Know Cancer

forgot password

A Phase II Study of St. John's Wort for the Treatment of Hot Flashes in Women With a History of Breast Cancer

Phase 2
18 Years
Not Enrolling
Breast Cancer, Hot Flashes

Thank you

Trial Information

A Phase II Study of St. John's Wort for the Treatment of Hot Flashes in Women With a History of Breast Cancer



- Determine the efficacy of Hypericum perforatum (St. John's wort) in alleviating hot
flashes, in terms of hot flash frequency, score, and duration and disruption of daily
activities caused by hot flashes, in postmenopausal women with non-metastatic breast

- Determine hot flash changes over 4 weeks in patients treated with this drug.


- Determine the toxicity of this drug in these patients.

- Determine the effect of Hypericum perforatum (St. John's wort) on serum tamoxifen
levels in women receiving tamoxifen therapy.

- Determine the effect of Hypericum perforatum (St. John's wort) on general
health-related quality of life and mood at 2 and 4 weeks relative to baseline, and
during the 2 week post-treatment phase in these patients.

- To evaluate changes in average weekly hot flush scores and duration over course of

OUTLINE: This is a multicenter study.

Patients receive oral Hypericum perforatum (St. John's wort) three times daily for 4 weeks
in the absence of disease progression or unacceptable toxicity.

Patients complete a daily diary of the frequency, severity, and duration of their hot
flashes, and complete quality of life and mood assessments every 2 weeks during study
treatment and continuing weekly for 2 weeks after completion of study treatment.

Patients receiving tamoxifen will have blood tests to measure serum tamoxifen levels at
baseline, 2, 4, and 6 weeks.

PROJECTED ACCRUAL: A total of 39 patients will be accrued for this study.

Inclusion Criteria


- Diagnosis of 1 of the following:

- Noninvasive ductal carcinoma in situ

- Localized breast cancer

- Stage 0-IIIB disease

- Locally recurrent breast cancer that is post-treatment AND disease-free for ≥ 2

- Experiencing ≥ 3 hot flashes per day (≥ 21 per week), defined by sweating, flushing,
sensation of warmth, night sweats, and/or rapid heart beat of sufficient severity
that the patient desires therapeutic intervention

- Normal mammogram within the past 10 months

- Hormone receptor status:

- Not specified



- 18 and over


- Female

Menopausal status

- Post-menopausal (i.e., no menstrual periods ≥ 12 months or surgical menopause)

Performance status

- ECOG 0-2

Life expectancy

- Not specified


- Not specified


- Bilirubin < 2 mg/dL

- SGOT ≤ 2 times normal


- Not specified


- Not pregnant or nursing

- Fertile patients must use effective contraception

- No history of intolerance to St. John's wort


Biologic therapy

- Not specified


- No concurrent cytotoxic chemotherapy

Endocrine therapy

- No concurrent selective estrogen-receptor modulators or aromatase inhibitors (e.g.,
anastrozole, letrozole, or exemestane) allowed

- Concurrent tamoxifen allowed

- No concurrent estrogen, progestational agents, or androgens for the alleviation of
hot flashes

- No concurrent corticosteroids


- Not specified


- Not specified


- More than 14 days since prior Hypericum perforatum (St. John's wort), monoamine
oxidase inhibitors, selective serotonin reuptake inhibitors (e.g., sertraline,
paroxetine, or fluoxetine) or selective norepinephrine reuptake inhibitors (e.g.,

- No concurrent use of any of the following:

- Antidepressants

- Theophylline

- Warfarin, unless for central line prophylaxis

- Protease inhibitors for AIDS

- Digoxin

- Cyclosporine

- Benzodiazepines (e.g., diazepam or alprazolam)

- Calcium-channel blockers (e.g., diltiazem or nifedipine)

- Coenzyme A reductase inhibitors for serum cholesterol reduction

- Macrolide antibiotics (e.g., azithromycin, erythromycin, or clarithromycin)

- Griseofulvin

- Phenobarbital

- Phenytoin

- Rifampin

- Rifabutin

- Grapefruit juice

- Other naturopathic or herbal products

- Ketoconazole

- Fluconazole

- Itraconazole

- Rifabutin

- No other concurrent medications for the alleviation of hot flashes (e.g., clonidine
or bellamine)

Type of Study:


Study Design:

Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care

Outcome Measure:

Effects of St. John's wort on mild to moderate hot flashes as measured by hot flash diary at baseline to 4 weeks

Outcome Time Frame:

One year

Safety Issue:


Principal Investigator

Michelle Naughton, PhD

Investigator Role:

Study Chair

Investigator Affiliation:

Comprehensive Cancer Center of Wake Forest University


United States: Food and Drug Administration

Study ID:

CCCWFU 98301



Start Date:

March 2006

Completion Date:

November 2008

Related Keywords:

  • Breast Cancer
  • Hot Flashes
  • recurrent breast cancer
  • stage I breast cancer
  • stage II breast cancer
  • stage IIIA breast cancer
  • stage IIIB breast cancer
  • breast cancer in situ
  • ductal breast carcinoma in situ
  • hot flashes
  • Breast Neoplasms
  • Hot Flashes



CCOP - Upstate Carolina Spartanburg, South Carolina  29303
CCOP - Southeast Cancer Control Consortium Winston-Salem, North Carolina  27104-4241
CCOP - Metro-Minnesota Saint Louis Park, Minnesota  55416
CCOP - Michigan Cancer Research Consortium Ann Arbor, Michigan  48106
CCOP - Central Illinois Springfield, Illinois  62526
Cancer Research for the Ozarks Springfield, Missouri  65807
CCOP - Greenville Greenville, South Carolina  29615
CCOP - Northern Indiana CR Consortium South Bend, Indiana  46601
CCOP - St. Louis-Cape Girardeau Saint Louis, Missouri  63141
CCOP - Beaumont Royal Oak, Michigan  48073-6769
Wake Forest University Comprehensive Cancer Center Winston-Salem, North Carolina  27157-1096
MBCCOP - Howard University Cancer Center Washington, District of Columbia  20060
Feist-Weiller Cancer Center at Louisiana State University Health Sciences Shreveport, Louisiana  71130-3932
University of Miami Sylvester Comprehensive Cancer Center - Miami Miami, Florida  33136
Leo W. Jenkins Cancer Center at ECU Medical School Greenville, North Carolina  27834
Alamance Cancer Center at Alamance Regional Medical Center Burlington, North Carolina  27216
Hugh Chatham Memorial Hospital Elkin, North Carolina  28621
Helen F. Graham Cancer Center at Christiana Hospital Newark, Delaware  19718
South Carolina Cancer Specialists Hilton Head Island, South Carolina  29925